PTGER1 and colorectal carcinoma: Recent studies on the EP1 antagonist (ONO-8711) and the EP4 antagonist (ONO-AE2-227; Grapiprant) indicate that EP4 receptor antagonists show greater potential in treating pain, inflammation and solid tumors including CRC [165,277].